ARTICLE | Clinical News
Lifitegrast: Phase III data
November 2, 2015 8:00 AM UTC
Top-line data from the double-blind, U.S. Phase III OPUS-3 trial in about 700 patients with dry eye disease showed that twice-daily 5% lifitegrast met the primary endpoint of improving patient-reporte...